Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026)

Revolution Medicines' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (changed 0.0% YoY), while the FY2025 annual figure was $2.4 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $2.4 million, roughly flat from $2.4 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $7.4 million in Q1 2022, with the low at $2.4 million in Q4 2024.
• The 5-year median for Non-Current Deferred Tax Liability is $3.1 million (2023), against an average of $4.3 million.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability changed 0.0% in 2022, then plunged 55.82% in 2023.
• Revolution Medicines' Non-Current Deferred Tax Liability stood at $7.0 million in 2022, then plunged by 55.66% to $3.1 million in 2023, then fell by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
• Business Quant data shows RVMD's Non-Current Deferred Tax Liability at $2.4 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.